| Full Name | Mary Bruer |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 198 Unity Road, Albion, Maine |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386327765 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | PR71603 (Maine) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mary Bruer, PHARMD 198 Unity Road, Albion, ME 04910 Ph: (207) 877-5064 | Mary Bruer, PHARMD 198 Unity Road, Albion, ME 04910 Ph: (207) 877-5064 |
News Archive
Celsion Corporation, a biotechnology drug development company, today announced financial results for the second quarter and six months ended June 30, 2010 and addressed the progression of the clinical trials of ThermoDox, Celsion's heat activated liposomal encapsulation of doxorubicin. ThermoDox is currently being evaluated in the Phase III HEAT trial for the treatment of hepatocellular carcinoma and in a Phase I/II trial for patients with recurrent chest wall breast cancer.
If current trends in the use of online education continue, 50% of continuing medical education (CME) used by physicians will be delivered via the Internet in 2016. This would represent a dramatic increase over the 9% of CME delivered via the Internet in 2008.
Researchers at Georgetown University Medical Center say they now have a clearer picture of how an extract from the leaves of the Ginkgo biloba tree reduces the risk of aggressive cancer in animal experiments.
The Leukemia & Lymphoma Society (LLS) and Shape Pharmaceuticals announced today that they have entered into a partnership to advance Shape's novel, topical treatment for cutaneous T-Cell lymphoma (CTCL) into clinical development. The compound, SHP-141, is a first-in-class topical histone deacetylase inhibitor with the potential to treat both early- and late-stage CTCL.
› Verified 2 days ago